News

Timely rescue therapy use during a myasthenic crisis — a life-threatening complication of myasthenia gravis (MG) marked by severe breathing problems — can reduce mortality among patients. That’s according to new findings from researchers in China, who investigated risk factors associated with prolonged mechanical ventilation, which is commonly…

NMD Pharma has been cleared by the U.S. Food and Drug Administration (FDA) to start a Phase 2b clinical trial testing NMD670, an investigational CIC-1 inhibitor being developed for generalized myasthenia gravis (gMG). Planned to launch in the coming months in the U.S. and Europe, the trial will…

Enspryng (satralizumab), which Chugai Pharmaceutical is testing for generalized myasthenia gravis (gMG), showed a significant benefit in easing disease symptoms and their impact on daily life when used along with standard of care. Positive results from the placebo-controlled Phase 3 LUMINESCE trial (NCT04963270), however, did not…

A 64-year-old woman with dropped head syndrome was found to have a form of myasthenia gravis (MG) associated with the presence of antibodies against a protein called muscle-specific kinase (MuSK) and axial myopathy, a condition where muscles that protect the spine become weak. Previous studies have reported axial myopathy…

All United for MG has opened a petition in Europe supporting myasthenia gravis (MG) patient and caregiver rights, including those promoting a higher quality of life and access to better healthcare and resources. The petition hopes to gain momentum following Rare Disease Day in February and ahead of…

Regulators in the U.K. have approved UCB’s Rystiggo (rozanolixizumab) as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are positive for antibodies that target the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK). The decision from the Medicines and Healthcare products Regulatory Agency (MHRA) comes…

Clinical responses to the approved generalized myasthenia gravis (gMG) therapy Zilbrysq (zilucoplan) have now been sustained for more than a year among adults given long-term treatment, according to interim analyses of the Phase 3 RAISE-XT open-label extension (OLE) study. For patients who switched from a placebo in earlier clinical…

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) consistently reduced disease severity and improved quality of life across treatment cycles among adults with generalized myasthenia gravis (gMG) in an open-label extension study. With each monthlong cycle of the injectable therapy, most patients achieved a clinically meaningful reduction in the severity…

A single dose of IASO Bio’s experimental BCMA CAR T-cell therapy equecabtagene autoleucel (CT103A) led to sustained physical function gains in two people with hard-to-treat myasthenia gravis (MG), a recent study suggests. “In our study, it is gratifying to see that BCMA CAR-T cell therapy can prevent MG…

Switching from maintenance therapeutic plasma exchange (TPE) to Vyvgart (efgartigimod) appeared to be well tolerated and effective for people with myasthenia gravis (MG), a short report suggests. “The good clinical response of this patient cohort, together with greater accessibility and convenience of infusion-based therapy, are notable advantages…